Andrade Robert

Average Profitability
<0.0001%
Insider Buys Quantity
1
Insider Buys Sum
$0
Insider Sells Quantity
10
Insider Sells Sum
$1.06M

Insider Activity of Andrade Robert

According to the SEC Form 4 filings, Andrade Robert, being in a position of

  1. CHIEF FINANCIAL OFFICER at Fennec Pharmaceuticals Inc.,
    оver the last 12 months, has bought 0 shares, and sold 57950 shares for $621,786,
    over all time since 2022-12-28, has bought 12500 shares for $0, and sold 104950 shares for $1.06M.

The largest sale of all time was on 2024-01-04 and amounted to 15000 shares of Fennec Pharmaceuticals Inc. for $159,600.

Biography of Andrade Robert

No biography is available at this moment.

2024-04-01PurchaseFennec Pharmaceuticals Inc.
FENC
CHIEF FINANCIAL OFFICER
12,500
$0$0-40.36%
2024-03-26SaleFennec Pharmaceuticals Inc.
FENC
CHIEF FINANCIAL OFFICER
13,975
0.0517%
$10.90$152,346-40.05%
2024-03-25SaleFennec Pharmaceuticals Inc.
FENC
CHIEF FINANCIAL OFFICER
13,975
0.0517%
$11.00$153,690-40.41%
2024-01-05SaleFennec Pharmaceuticals Inc.
FENC
CHIEF FINANCIAL OFFICER
15,000
0.0563%
$10.41$156,150-29.87%
2024-01-04SaleFennec Pharmaceuticals Inc.
FENC
CHIEF FINANCIAL OFFICER
15,000
0.0563%
$10.64$159,600-30.91%
2023-06-30SaleFennec Pharmaceuticals Inc.
FENC
CHIEF FINANCIAL OFFICER
7,500
0.0282%
$8.82$66,150-2.04%
2023-06-29SaleFennec Pharmaceuticals Inc.
FENC
CHIEF FINANCIAL OFFICER
7,500
0.0286%
$8.97$67,275-1.92%
2023-06-28SaleFennec Pharmaceuticals Inc.
FENC
CHIEF FINANCIAL OFFICER
10,000
0.0364%
$8.99$89,900-5.81%
2022-12-30SaleFennec Pharmaceuticals Inc.
FENC
CHIEF FINANCIAL OFFICER
5,500
0.021%
$9.61$52,867-12.6%
2022-12-29SaleFennec Pharmaceuticals Inc.
FENC
CHIEF FINANCIAL OFFICER
5,500
0.0207%
$9.57$52,661-13.27%
2022-12-28SaleFennec Pharmaceuticals Inc.
FENC
CHIEF FINANCIAL OFFICER
11,000
0.0422%
$9.61$105,760-11.91%
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.